TrioBiotics Pharma AG
Triton BioPharma Submits Product Development Application to U.S. Department of Defense’s Congressionally Directed Medical Research Program regarding Post-traumatic Stress Disorder Research
Triton Biopharma AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- January 15th, 2009 Triton BioPharma Submits Product Development Application to U.S. Department of Defense’s Congressionally Directed Medical Research Program regarding Post-traumatic Stress Disorder Research Zug, Switzerland – January 15th, 2009 – TRITON BIOPHARMA AG (Frankfurt: 4ON) announced today that its wholly-owned R&D subsidiary company, Triton BioPharma LLC, has submitted a grant proposal to the U.S. Department of Defense’s Congressionally Directed Medical Research Program (CDMRP). This Deployment Related Medical Research Program funding opportunity is for an Advanced Technology/Therapeutic Development Award of up to $5 million per year, for a total potential award of $25 million over five years. Triton’s product development pipeline includes drug leads which address psychological health gaps related to deployment and affecting millions of military service members and their families. Exposure to multiple stressors and combat experiences may lead to symptoms of post-traumatic stress disorder (PTSD), depression and anxiety, impeding the ability of veterans to adjust and reintegrate into family and society. These disorders have also been linked to behaviors with greater health risk to heath including prevalence for smoking, alcohol and substance abuse. Unfortunately, medications in current use often present delayed onset of action or a lack of therapeutic benefit in some patients and may be associated with serious adverse effects. Triton targets the preclinical development of secondary metabolites isolated from marine sources as new therapeutic drug leads for a number of disease targets and includes PTSD, depression, anxiety and other psychological conditions. In collaboration with researchers of a number of US institutions, including the University of Hawaii at Manoa and the University of Mississippi, the project will develop key marine alkaloids shown to exhibit anxiolytic and antidepressant-like action upon evaluation using established animal models. These lead molecules are the subject of recent US and PCT patent applications filed by Triton with regard to utility in the treatment of depression, anxiety, obsessive-compulsive disorders, PTSD, sleep disorders, eating disorders and other neuropsychiatric disorders. 'Triton’s product development pipeline is scientifically very sound making it highly competitive for grant opportunities', stated Dr. Mark Hamann, Director and CSO of Triton Biopharma. 'It only makes good sense to apply for resources with agencies such as the DOD, NIH, NSF, NOAA and USDA, which have been supporting the academic discovery efforts generating much of the biotechnology pipeline.' 'Applying for competitive research funding to advance our research programs is a core strategy of our drug development plan', stated Angelo Boujos, Chairman & CEO of Triton BioPharma AG. 'The adverse social and economic impact of these mental health issues is enormous and this is an opportunity to develop new and more effective classes of drug leads in treatment of these conditions for improved quality of life.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton’s biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. With a commitment to cooperation in innovation, Triton brings together a significant network of international collaborators, consultants and industry specialists in the areas of microbiology, pharmacology, synthetic and organic chemistry, marine natural products and biochemistry. Accessing this critical mass of scientific experts and utilizing research facilities worldwide is a principal component of its drug discovery and development strategy. Triton’s current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. For more information, visit www.tritonbiopharma.com. Contact: Investor Relations Europe: Milestone Media AG, Zug (Switzerland) Phone: +41 (0) 41 5000 769 Fax: +41 (0) 41 5000 728 E-mail: info@milestonemedia.ch 15.01.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found